ArticlePlastic and reconstructive surgery2020
The Costs of Breast Reconstruction and Implications for Episode-Based Bundled Payment Models.
Article in Plastic and reconstructive surgery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 33 citations in OpenAlex.
- Analysis of Career Outcomes and Practice Patterns After Microsurgery Fellowship.Plastic and reconstructive surgery. Global open · 2026Article
- Microbial Contamination-Mediated Inflammation Is a Major Contributor of Breast Implant Complications: Prospective Analysis of 631 Samples.Journal of clinical medicine · 2026Article
- Nipple-Sparing Mastectomy and Infection Risk after Immediate Breast Reconstruction.Journal of the American College of Surgeons · 2025Article
- Quantification of Chest Wall Asymmetry in Healthy Females Using Standardized Computed Tomography-Derived Curve Modeling: A Proof of Concept.Aesthetic surgery journal. Open forum · 2025Article
- National trends in revision procedures in post-mastectomy breast reconstruction: Autologous vs implant-based approaches.Journal of plastic, reconstructive & aesthetic surgery : JPRAS · 2024Article
- Decreasing length of stay in breast reconstruction patients: A national analysis of 2019-2020.Journal of surgical oncology · 2023Article
- Variable Accessibility to Consumer Pricing Among Breast Cancer Operations.Annals of surgical oncology · 2023Article
- Complications, Costs, and Healthcare Resource Utilization After Staged, Delayed, and Immediate Free-Flap Breast Reconstruction: A Longitudinal, Claims-Based Analysis.Annals of surgical oncology · 2023Article
- Defining the Value of Breast Reconstruction Surgeons: Quantifying Clinical Encounter and Operative Volume at an Academic Center.Plastic and reconstructive surgery. Global open · 2022Article
- Article
- Financial Toxicity Considerations in Breast Reconstruction: Recommendations for Research and Practice.Women's health issues : official publication of the Jacobs Institute of Women's HealthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
backgroundImplementation of payment reform for breast reconstruction following mastectomy demands a comprehensive understanding of costs related to the complex process of reconstruction. Bundled payments for services to women with breast cancer may profoundly impact reimbursement and access to breast reconstruction. The authors' objectives were to determine the contribution of cancer therapies, comorbidities, revisions, and complications to costs following immediate reconstruction and the optimal duration of episodes to incentivize cost containment for bundled payment models.
methodsThe cohort was composed of women who underwent immediate breast reconstruction between 2009 and 2016 from the MarketScan Commercial Claims and Encounters database. Continuous enrollment for 3 months before and 24 months after reconstruction was required. Total costs were calculated within predefined episodes (30 days, 90 days, 1 year, and 2 years). Multivariable models assessed predictors of costs.
resultsAmong 15,377 women in the analytic cohort, 11,592 (75 percent) underwent tissue expander, 1279 (8 percent) underwent direct-to-implant, and 2506 (16 percent) underwent autologous reconstruction. Adjuvant therapies increased costs at 1 year [tissue expander, $39,978 (p < 0.001); direct-to-implant, $34,365 (p < 0.001); and autologous, $29,226 (p < 0.001)]. At 1 year, most patients had undergone tissue expander exchange (76 percent) and revisions (81 percent), and a majority of complications had occurred (87 percent). Comorbidities, revisions, and complications increased costs for all episode scenarios.
conclusionsEpisode-based bundling should consider separate bundles for medical and surgical care with adjustment for procedure type, cancer therapies, and comorbidities to limit the adverse impact on access to reconstruction. The authors' findings suggest that a 1-year time horizon may optimally capture reconstruction events and complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.